AbCellera Biologics Inc. Files 8-K
Ticker: ABCL · Form: 8-K · Filed: May 14, 2025 · CIK: 1703057
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
AbCellera filed a routine 8-K, no major news.
AI Summary
AbCellera Biologics Inc. filed an 8-K on May 14, 2025, reporting other events and financial statements. The filing does not contain specific details about new material events, acquisitions, or financial performance beyond the standard reporting requirements.
Why It Matters
This filing indicates AbCellera Biologics Inc. is providing routine updates to the SEC, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and does not disclose any new material events or risks.
Key Players & Entities
- AbCellera Biologics Inc. (company) — Registrant
- May 14, 2025 (date) — Date of Report
- Vancouver, BC (location) — Principal Executive Office
FAQ
What is the purpose of this 8-K filing by AbCellera Biologics Inc.?
The 8-K filing on May 14, 2025, is for reporting 'Other Events' and 'Financial Statements and Exhibits' as per SEC regulations.
Does this filing announce any new material events for AbCellera Biologics Inc.?
The filing does not specify any new material events beyond the standard reporting categories of 'Other Events' and 'Financial Statements and Exhibits'.
What is AbCellera Biologics Inc.'s principal executive office address?
AbCellera Biologics Inc.'s principal executive office is located at 150 W 4th Avenue, Vancouver, BC V5Y 1G6.
What is the filing date for this 8-K?
The filing date for this 8-K report is May 14, 2025.
What is AbCellera Biologics Inc.'s state of incorporation?
AbCellera Biologics Inc. is incorporated in British Columbia.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 14, 2025 regarding AbCellera Biologics Inc. (ABCL).